 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Growth factor
|
PDB id
|
|
|
|
1rml
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Growth factor
|
 |
|
Title:
|
 |
Nmr study of acid fibroblast growth factor bound to 1,3,6- naphthalene trisulphonate, 26 structures
|
|
Structure:
|
 |
Acidic fibroblast growth factor. Chain: a. Fragment: residues 23 - 154. Synonym: heparin-binding growth factor 1. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 562.
|
|
NMR struc:
|
 |
26 models
|
 |
|
Authors:
|
 |
R.M.Lozano,M.A.Jimenez,J.Santoro,M.Rico,G.Gimenez-Gallego
|
Key ref:
|
 |
R.M.Lozano
et al.
(1998).
Solution structure of acidic fibroblast growth factor bound to 1,3, 6-naphthalenetrisulfonate: a minimal model for the anti-tumoral action of suramins and suradistas.
J Mol Biol,
281,
899-915.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
21-May-98
|
Release date:
|
11-Nov-98
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
|
|
P05230
(FGF1_HUMAN) -
Heparin-binding growth factor 1
|
|
|
|
Seq: Struc:
|
 |
 |
 |
155 a.a.
131 a.a.
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
extracellular region
|
8 terms
|
 |
|
Biological process
|
multicellular organismal development
|
22 terms
|
 |
|
Biochemical function
|
protein binding
|
6 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Mol Biol
281:899-915
(1998)
|
|
PubMed id:
|
|
|
|
|
| |
|
Solution structure of acidic fibroblast growth factor bound to 1,3, 6-naphthalenetrisulfonate: a minimal model for the anti-tumoral action of suramins and suradistas.
|
|
R.M.Lozano,
M.Jiménez,
J.Santoro,
M.Rico,
G.Giménez-Gallego.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Recent data show that anti-angiogenesis may provide a promising route to treat
cancer. Fibroblast growth factors (FGFs) are powerful angiogenic polypeptides,
whose mitogenic activity requires the presence of heparin-like compounds. It has
been shown that angiogenesis promoted by FGFs on inhibition by monoclonal
antibodies and antisense targeting can also inhibit tumour growth. Derivatives
of suramin, a polysulfonated binaphthyl urea and binaphthylsulfonated
derivatives of distamycin, suradistas, constitute an important group of
potential anti-cancer agents. These compounds compete with heparin in forming
tight complexes with FGFs. This inhibits the recognition of these growth factors
by their tyrosine kinase membrane receptors thereby suppressing their angiogenic
activity. Here we show that 1,3,6-naphthalenetrisulfonate, a common chemical
function of the suramins and suradistas with the highest anti-angiogenic
activity inhibits the mitogenic activity of acidic fibroblast growth factor, and
that this inhibition is relieved by increasing concentrations of heparin in the
assay. We have also solved the three-dimensional structure in solution of the
protein complexed to this compound. The structural data provide clues that may
help in understanding the inhibitory effect of suramins and suradistas, and
could contribute to the development of new anti-tumoral drugs.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 4.
Figure 4. Differences in d-values between the NH amide (A)
and C^aH (B) protons for each residue in NTS and MIHS-bound aFGF.
|
 |
Figure 9.
Figure 9. Surface of the mean structures of NTS (left) and
MIHS-bound (right) aFGF color mapped with the electrostatic
potential (red, negative; blue, positive), showing the residues,
highlighted in Figure 8, that presumably interact with the
tyrosine kinase cell membrane receptors. Residues whose
interaction is suggested by visual inspection of the region
defined by the ones identified by point-directed mutagenesis
(green color in Figure 8) are labelled with an asterisk (*).
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Elsevier:
J Mol Biol
(1998,
281,
899-915)
copyright 1998.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
J.L.Barneto,
M.Avalos,
R.Babiano,
P.Cintas,
J.L.Jiménez,
and
J.C.Palacios
(2010).
A new model for mapping the peptide backbone: predicting proton chemical shifts in proteins.
|
| |
Org Biomol Chem, 8,
857-863.
|
 |
|
|
|
|
 |
S.Cochran,
C.P.Li,
and
V.Ferro
(2009).
A surface plasmon resonance-based solution affinity assay for heparan sulfate-binding proteins.
|
| |
Glycoconj J, 26,
577-587.
|
 |
|
|
|
|
 |
P.Cuevas,
D.Díaz-González,
C.García-Martín-Córdova,
I.Sánchez,
R.M.Lozano,
G.Giménez-Gallego,
and
M.Dujovny
(2006).
Dobesilate diminishes activation of the mitogen-activated protein kinase ERK1/2 in glioma cells.
|
| |
J Cell Mol Med, 10,
225-230.
|
 |
|
|
|
|
 |
S.Cochran,
C.P.Li,
and
I.Bytheway
(2005).
An experimental and molecular-modeling study of the binding of linked sulfated tetracyclitols to FGF-1 and FGF-2.
|
| |
Chembiochem, 6,
1882-1890.
|
 |
|
|
|
|
 |
C.Fernández-Tornero,
R.M.Lozano,
M.Redondo-Horcajo,
A.M.Gómez,
J.C.López,
E.Quesada,
C.Uriel,
S.Valverde,
P.Cuevas,
A.Romero,
and
G.Giménez-Gallego
(2003).
Leads for development of new naphthalenesulfonate derivatives with enhanced antiangiogenic activity: crystal structure of acidic fibroblast growth factor in complex with 5-amino-2-naphthalene sulfonate.
|
| |
J Biol Chem, 278,
21774-21781.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
E.De Lorenzi,
S.Grossi,
G.Massolini,
S.Giorgetti,
P.Mangione,
A.Andreola,
F.Chiti,
V.Bellotti,
and
G.Caccialanza
(2002).
Capillary electrophoresis investigation of a partially unfolded conformation of beta(2)-microglobulin.
|
| |
Electrophoresis, 23,
918-925.
|
 |
|
|
|
|
 |
M.Zamai,
C.Hariharan,
D.Pines,
M.Safran,
A.Yayon,
V.R.Caiolfa,
R.Cohen-Luria,
E.Pines,
and
A.H.Parola
(2002).
Nature of Interaction between basic fibroblast growth factor and the antiangiogenic drug 7,7-(carbonyl-bis[imino-N-methyl-4,2-pyrrolecarbonylimino[N-methyl-4,2-pyrrole]-carbonylimino])-bis-(1,3-naphtalene disulfonate). II. Removal of polar interactions affects protein folding.
|
| |
Biophys J, 82,
2652-2664.
|
 |
|
|
|
|
 |
N.Lehmann,
G.Krishna Aradhyam,
and
K.Fahmy
(2002).
Suramin affects coupling of rhodopsin to transducin.
|
| |
Biophys J, 82,
793-802.
|
 |
|
|
|
|
 |
A.Matter
(2001).
Tumor angiogenesis as a therapeutic target.
|
| |
Drug Discov Today, 6,
1005-1024.
|
 |
|
|
|
|
 |
H.J.Hecht,
R.Adar,
B.Hofmann,
O.Bogin,
H.Weich,
and
A.Yayon
(2001).
Structure of fibroblast growth factor 9 shows a symmetric dimer with unique receptor- and heparin-binding interfaces.
|
| |
Acta Crystallogr D Biol Crystallogr, 57,
378-384.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
Y.V.Fedorov,
R.S.Rosenthal,
and
B.B.Olwin
(2001).
Oncogenic Ras-induced proliferation requires autocrine fibroblast growth factor 2 signaling in skeletal muscle cells.
|
| |
J Cell Biol, 152,
1301-1305.
|
 |
|
|
|
|
 |
M.Guzmán-Casado,
J.M.Sánchez-Ruiz,
M.El Harrous,
G.Giménez-Gallego,
and
A.Parody-Morreale
(2000).
Energetics of myo-inositol hexasulfate binding to human acidic fibroblast growth factor effect of ionic strength and temperature.
|
| |
Eur J Biochem, 267,
3477-3486.
|
 |
|
|
|
|
 |
R.M.Lozano,
A.Pineda-Lucena,
C.Gonzalez,
M.Angeles Jiménez,
P.Cuevas,
M.Redondo-Horcajo,
J.M.Sanz,
M.Rico,
and
G.Giménez-Gallego
(2000).
1H NMR structural characterization of a nonmitogenic, vasodilatory, ischemia-protector and neuromodulatory acidic fibroblast growth factor.
|
| |
Biochemistry, 39,
4982-4993.
|
 |
|
PDB codes:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
|